Literature DB >> 8437822

Corticosteroid-induced ocular hypertension in the treatment of aphakic or pseudophakic cystoid macular edema.

N S Melberg1, R J Olk.   

Abstract

PURPOSE: To examine the relationship between corticosteroid-induced ocular hypertension and the reduction and/or resolution of chronic aphakic or pseudophakic cystoid macular edema (CME).
METHODS: The authors retrospectively reviewed 454 cases coded for CME between 1971 and 1991 and identified 21 patients with aphakic or pseudophakic CME greater than 6 months' duration who experienced a documented rise in intraocular pressure (IOP) on corticosteroid therapy. These patients were compared with similarly treated controls who did not experience a rise in IOP, and visual acuity and the biomicroscopic appearance of CME were examined.
RESULTS: Sixteen of 21 patients showed improved visual acuity and reduction and/or resolution of CME. In all five cases of treatment failure, there was evidence of vitreous attachment to anterior segment structures. This is statistically significant compared with controls, in which 4 of 14 patients with normal vitreous anatomy showed similar improvement (P = 0.00003).
CONCLUSION: This small retrospective series suggests that in the absence of vitreous traction, corticosteroid-induced ocular hypertension possibly leads to reduction and/or resolution of chronic aphakic or pseudophakic cystoid macular edema.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437822     DOI: 10.1016/s0161-6420(93)31675-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  2 in total

1.  Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema.

Authors:  Emily Y Chew; Adam R Glassman; Roy W Beck; Neil M Bressler; Gary E Fish; Fredrick L Ferris; James L Kinyoun
Journal:  Retina       Date:  2011-02       Impact factor: 4.256

2.  Steroid Treatment in Macular Edema: A Bibliometric Study and Visualization Analysis.

Authors:  Yu Lin; Xiang Ren; Danian Chen
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.